

## News Release

Lonza Group Ltd  
Muenchensteinerstrasse 38  
4002 Basel, Switzerland  
www.lonza.com

ORGANOBALANCE GmbH  
Gustav-Meyer-Allee 25  
13355 Berlin, Germany  
www.organobalance.com

### **Lonza and ORGANOBALANCE Enter Global License Agreement to Develop and Market Unique Probiotic, *Lactobacillus anti-H. pylori***

Basel, Switzerland and Berlin, Germany, 19 April 2011 – Lonza and ORGANOBALANCE today announced the signing of a worldwide exclusive license agreement in which Lonza will develop, produce and commercialize products containing a probiotic *Lactobacillus* strain. Developed by ORGANOBALANCE GmbH, the probiotic strain acts against *Helicobacter pylori* (*H. pylori*). Research shows that *H. pylori* has been implicated as a common cause of peptic ulcers and gastritis.

Currently, about 50 percent of the global population is infected with *H. pylori* (Source: Czinn SJ. J Pediatr. 2005 Mar;146 (3 Suppl):S21-6.). However, this new probiotic strain demonstrates great potential in helping to maintain a balanced *H. pylori* concentration. Utilizing a unique patent-protected mode of action, *Lactobacillus anti-H. pylori* binds to *H. pylori* in the stomach, thus creating large aggregates, which are subsequently flushed out of the stomach and excreted.

“This agreement with ORGANOBALANCE creates a basis for Lonza to enter the probiotic market -a market with vast growth potential- with a unique ingredient,” said Roman Quinter, Senior Vice President and Head of Nutrition Ingredients business for Lonza. “Lonza is a global leader in the manufacturing of intermediates and API’s for the pharmaceutical industry through biotechnology and fermentation. Integrating the *Lactobacillus anti-H. pylori* strain into our nutrition ingredient portfolio provides an opportunity to leverage our strong biotech expertise and knowledge to provide a highly effective product to the nutrition landscape.”

Produced via a fermentation process, the *Lactobacillus anti-H. pylori* strain is patent-protected. The strain demonstrates probiotic activity by gently, yet highly effectively, removing *H. pylori* from the stomach.

“As the leader in the development of innovative probiotic strains, we regard this agreement with Lonza as a further recognition of ORGANOBALANCE’s strategy, our expertise, and our innovative capacity,” said Prof. Dr. Christine Lang, CEO of ORGANOBALANCE GmbH. “We highly appreciate Lonza’s dedication to lead our development into great success on the nutrition marketplace.”

#### **About Lonza**

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2010, the company had sales of CHF 2.680 billion. Further information can be found at [www.lonza.com](http://www.lonza.com).

### **About ORGANO BALANCE**

ORGANO BALANCE GmbH is a company specialising in strain development and microbiological screening, tapping the potential of beneficial microorganisms, known as specific probiotic cultures, in order to balance out the microflora and restore the microbial equilibrium in a natural way. In close cooperation with renowned industry partners, ORGANO BALANCE GmbH develops new biological products in the fields of pharmaceuticals, preventive health care, nutrition and cosmetics. In its development activities the company draws on its own collection of more than 8000 microorganisms suitable for use in foodstuffs as well as its own OASSYS® screening systems. ORGANO BALANCE was founded in 2001 and is based in Berlin, Germany. More information can be found at [www.organobalance.com](http://www.organobalance.com).

For further information please contact:

Lonza Ltd  
Marketing Manager Nutrition  
Adriana Williams  
Tel +41 61 316 8626  
Fax + 41 61 316 9626  
[adriana.williams@lonza.com](mailto:adriana.williams@lonza.com)

Lonza Group  
Head of External Communications  
Melanie Disa  
Tel +1 201 316 9413  
Fax +1 201 696 3533  
[melanie.disa@lonza.com](mailto:melanie.disa@lonza.com)

ORGANO BALANCE GmbH  
Kristin Ebert  
Gustav-Meyer-Allee 25  
13355 Berlin  
Germany  
Tel +49 30 46307-200  
Fax +49 30 46307-210  
[info@organobalance.com](mailto:info@organobalance.com)  
[www.organobalance.com](http://www.organobalance.com)

Press contact for ORGANO BALANCE GmbH:

COMAGO  
Communication . Marketing . Organisation  
Helmut Landenberger  
Wiesenstrasse 55  
14612 Falkensee  
Germany  
Tel +49 33 22 84 06 52  
Fax +49 33 22 84 06 53  
[mail@comago.de](mailto:mail@comago.de)  
[www.comago.de](http://www.comago.de)